New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
04:55 EDTCYH, CYH, BAX, BAX, CAH, CAH, KND, KND, CRY, CRY, MDCO, MDCO, SRDX, SRDX, XOMA, XOMA, PRGO, PRGO, IDRA, IDRA, EBS, EBS, CVS, CVSRBC Capital to hold a conference
Healthcare Conference is being held in New York on February 25-26.
News For CYH;EBS;IDRA;PRGO;XOMA;SRDX;MDCO;CRY;KND;CAH;BAX;CVS From The Last 14 Days
Check below for free stories on CYH;EBS;IDRA;PRGO;XOMA;SRDX;MDCO;CRY;KND;CAH;BAX;CVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 7, 2014
16:20 EDTEBSEmergent BioSol' reports Q2 GAAP EPS 13c, may not compare with consensus 32c
Reports Q2 revenue $110.3M, consensus $109.25M.
16:17 EDTXOMAXOMA backs view of $55M-$60M cash used in ongoing ops in 2014
Subscribe for More Information
16:16 EDTXOMAXOMA reports Q2 EPS with gain (17c), consensus (21c)
Subscribe for More Information
15:19 EDTCVSCVS Caremark management to meet with FBR Capital
Subscribe for More Information
09:03 EDTBAXBaxter opens biologics facility in Singapore
Baxter International announced the formal opening of its first advanced recombinant biologic facility in Singapore, and expansion plans for a new recombinant protein processing suite. The current suite supports the processing of ADVATE.The second suite will initially process RIXUBIS, a recombinant factor IX protein for the treatment of adults with hemophilia B and, when operational, will be the primary global commercial processing facility. It will also support production of the company’s investigational extended half-life recombinant FVIII treatment BAX 855 upon regulatory approval. The Singapore facility received regulatory approval from the European Medicines Agency in January 2014 for the production of ADVATE2. This allows the facility to process and supply ADVATE to the European Union, Iceland and Norway. The biologics facility in Singapore currently employs more than 400 production staff and expects to reach 450 by 2015 to support the second processing suite.
08:36 EDTCRYCryoLife acquires distribution rights and purchase option for PhotoFix
Subscribe for More Information
08:14 EDTIDRAIdera Pharmaceuticals announces collaboration with TMA
Subscribe for More Information
08:12 EDTMDCOThe Medicines Co. to host conference call
Subscribe for More Information
07:13 EDTEBSEmergent BioSolutions submits BLA to FDA for AIGIV
Subscribe for More Information
05:11 EDTMDCOThe Medicines Co. Orbactiv approved by FDA
The Medicines Company announced that the FDA has approved Orbactiv for injection for the treatment of adults with acute bacterial skin and skin structure infections, or ABSSSI, caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus aureus. Orbactiv is the first and only antibiotic approved by FDA to treat ABSSSIs with a single, once-only administration. Once fully infused over three hours, the Orbactiv treatment regimen is complete for patients with skin infections caused by susceptible Gram-positive pathogens.
August 6, 2014
18:34 EDTKNDKindred Healthcare sees Q3 cont. ops diluted EPS 5c-15c, consensus 17c
Subscribe for More Information
18:32 EDTKNDKindred Healthcare sees FY14 cont. ops diluted EPS 96c-$1.14, consensus $1.14
The company revised its operating cash flow guidance range of $245M-$275M to a revised range of $200M-$230M. The company maintained its expectation of $100M-$105M for routine capital expenditures and for timing reasons reduced its anticipated FY14 cash outflows for development of new or replacement facilities by $5M to approximately $15M-$20M. The company expects its FY14 operating cash flows in excess of routine and development capital spending to approximate $85M-$105M, which will be available to fund acquisitions, repay debt and pay dividends. Estimated dividend payments for FY14 are expected to approximate $29M, an increase of approximately $3M from the previous guidance due to the issuance of 9.7M additional common shares in the company’s recently completed equity offering.
18:27 EDTKNDKindred Healthcare Q2 hospital division admissions growth up 3.1%
The company saw Q2 hospital division revenue growth per patient day of 1.8% and 1.3% growth in core operating costs per patient day. RehabCare division achieved sequential core operating income growth and margin improvement from 11.6% in Q1 to 12.3% in Q2. Nursing center division core operating income increased 11.3% primarily due to growth in revenues and operating margins were significantly improved due to ongoing repositioning and cost control initiatives. Care Management division delivered 66% revenue growth and core operating income doubled compared to the same period last year.
18:23 EDTKNDKindred Healthcare reports Q2 diluted continued ops EPS 34c, consensus 32c
Reports Q2 revenue $1.28B, consensus $1.28B. Q2 operating results included pretax charges of $70.9M, or 83c per diluted share related to debt refinancing, restructuring, litigation and transaction costs. Without these items, diluted earnings per share from continuing operations increased 26%.
18:17 EDTMDCOFDA approves Orbactiv to treat skin infections
Subscribe for More Information
16:28 EDTCAHCardinal Health authorizes $1B increase to share buyback program
Subscribe for More Information
08:21 EDTIDRAIdera Pharmaceuticals announces GSOs publication
Subscribe for More Information
07:47 EDTCVSRetailers pare store openings as shopper visits slide, WSJ says
Subscribe for More Information
06:26 EDTMDCOFDA PDUFA Date for The Medicines Company Oritavancin is August 6, 2014
06:21 EDTCAHPiper Jaffray to hold a summit
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use